Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Menu

    Ravulizumab-cwvz

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 3Alexion Pharma Canada, AstraZeneca Rare Disease

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    filter clear-filterReset all filters

    PharmaCompass
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Alexion Pharma Canada, Astra...

    RAVULIZUMAB
    arrow
    Aus. Peptide Conference
    Not Confirmed

    Alexion Pharma Canada, AstraZeneca Rare Di...

    Country
    arrow
    Aus. Peptide Conference
    Not Confirmed

    Patent Expiration Date : 2035-03-06

    Date Granted : 2022-11-08

    RAVULIZUMAB

    Brand Name : ULTOMIRIS

    Patent Number : 2942165

    Filing Date : 2015-03-06

    Strength per Unit : 10mg / mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : INTRAVENOUS

    Patent Expiration Date : 2035-03-06

    Date Granted : 2022-11-08

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Alexion Pharma Canada, Astra...

    RAVULIZUMAB
    arrow
    Aus. Peptide Conference
    Not Confirmed

    Alexion Pharma Canada, AstraZeneca Rare Di...

    Country
    arrow
    Aus. Peptide Conference
    Not Confirmed

    Patent Expiration Date : 2035-03-06

    Date Granted : 2022-11-08

    RAVULIZUMAB

    Brand Name : ULTOMIRIS

    Patent Number : 2942165

    Filing Date : 2015-03-06

    Strength per Unit : 100 mg / mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : INTRAVENOUS

    Patent Expiration Date : 2035-03-06

    Date Granted : 2022-11-08

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Alexion Pharma Canada, Astra...

    RAVULIZUMAB
    arrow
    Aus. Peptide Conference
    Not Confirmed

    Alexion Pharma Canada, AstraZeneca Rare Di...

    Country
    arrow
    Aus. Peptide Conference
    Not Confirmed

    Patent Expiration Date : 2035-03-06

    Date Granted : 2022-11-08

    RAVULIZUMAB

    Brand Name : ULTOMIRIS

    Patent Number : 2942165

    Filing Date : 2015-03-06

    Strength per Unit : 100 mg / mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : INTRAVENOUS

    Patent Expiration Date : 2035-03-06

    Date Granted : 2022-11-08

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF